Parkinson’s breakthrough: Researchers find way to halt disease progression

[JayPwP]

Unable to find any further information...

mcknights.com/news/clinical...

[jimcaster]

Unfortunately, the key words in the article are "in mice."

[bassofspades in reply to jimcaster]

Those lucky mice!!

[Xenos in reply to jimcaster]

I wonder if mice use humans for testing their drugs...

[JayPwP in reply to Xenos]

Good one

[MarionP in reply to Xenos]

Douglas Adams thought so.

[berti2206 in reply to jimcaster]

ça commence toujours ainsi et c'est très prometteur

[jimcaster in reply to berti2206]

Cela peut être encourageant, mais comme pour de nombreux autres essais sur souris réussis, je ne pense pas que je vivrai assez longtemps pour en bénéficier. J'espère que je me trompe.

[berti2206 in reply to jimcaster]

mon épouse a 38 ans, a été diagnostiquée il y a 5 ans. J'éspère qu'elle bénéficiera des nouvelles technologies rapidement...

[jimcaster in reply to berti2206]

Être diagnostiqué à 33 ans a dû être difficile. J'espère et je crois qu'une percée majeure viendra bientôt.

[JayPwP in reply to jimcaster]

The post is hijacked

Will need Google translate

[jimcaster in reply to JayPwP]

Sorry. I used Google translate to reply to Berti2206 in French simply because he originally replied in French.

[JayPwP in reply to jimcaster]

No issues jim

[park_bear]

here:

nature.com/articles/s41598-...

"For efficient knock down, we designed and synthesized an amido-bridged nucleic acids (AmNA)-modified antisense oligonucleotide (ASO) that targeted SNCA with improved stability and cellular uptake in vivo. AmNA-ASO efficiently downregulated SNCA at both the mRNA and protein level in vitro and in vivo. Notably, AmNA-ASO was efficiently delivered into the mouse brain by intracerebroventricular injection without the aid of additional chemicals. Furthermore, administration of AmNA-ASO ameliorated neurological defects in PD model mice expressing human wild type SNCA. Taken together, these findings suggest that AmNA-ASO is a promising therapeutic strategy for SNCA-associated pathology in PD."

Possibly helpful but it is a long way from an animal model that tries to replicate Parkinson's to approval for human use.

[Patrickk]

Bydureon, a repurposed Type 2 Diabetes drug is now in third-stage trials in UK for stopping Parkinson's in its tracks -- results expected 2023. Testing -- mice, open label, double blind -- has been going on for 10 years and it has been positive every time.

scienceofparkinsons.com/201...

[bubee]

Ten years. Geez what on earth could take that long.

[JayPwP in reply to bubee]

Missing intent

[Xenos in reply to bubee]

Vaccines...

[Fredzu]

Crew

[aspergerian]

The study:

Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease | 2020 pmc. Scientific Reports.

nature.com/articles/s41598-...